CD70/B7H3 targeted CAR-T therapy(Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameCD70/B7H3 targeted CAR-T therapy(Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy
Mechanisms of ActionCD70 antigen modulatorsCD276 antigen modulators
TargetsCD70 antigenCD276 antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Calmhome Cell and Gene Engineering Institute Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Calmhome Cell and Gene Engineering Institute Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A